Business
DICOT: LIB-01 demonstrated long-lasting efficacy in phase 2a, supporting further clinical development
DICOT: LIB-01 demonstrated long-lasting efficacy in phase 2a, supporting further clinical development
About this update from Dicot Pharma Ab
Positive phase 2a results for LIB-01 showed long-lasting efficacy and safety, supporting advancement to phase 2b. Strong financial position with SEK 69.2 million cash and 85.8% equity ratio, but continued losses and need for future funding remain. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.